MWNA
FOMX

Marshall Wace North America’s Foamix Pharmaceuticals Ltd. Ordinary Shares FOMX Stock Holding History

Marshall Wace North America’s Portfolio FOMX Stock Details FOMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-23,230
Closed -$83K – 2068
2018
Q4 		$83K Sell
23,230
-514,598
-96% -$2.24M ﹤0.01% 1125
2018
Q3 		$3.08M Buy
537,828
+122,328
+29% +$700K 0.02% 407
2018
Q2 		$2.08M Sell
415,500
-207,387
-33% -$1.07M 0.01% 755
2018
Q1 		$3.19M Sell
622,887
-5,357
-0.9% -$32.2K 0.02% 677
2017
Q4 		$3.78M Hold
628,244
– – 0.02% 661
2017
Q3 		$3.77M Sell
628,244
-4,575
-0.7% -$23.6K 0.02% 627
2017
Q2 		$3.16M Buy
632,819
+189,350
+43% +$845K 0.02% 622
2017
Q1 		$2.22M Buy
+443,469
New +$4.27M 0.02% 560

Other funds holding FOMX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Marshall Wace North America's FOMX Position: Q1 2019 in Review

Marshall Wace North America sold out of Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) in Q1 2019, closing a stake of 23,230 shares — an estimated $83K sold.

Marshall Wace North America first reported a position in FOMX in Q1 2017 and held it in 8 quarters. The position peaked at $3.78M in Q4 2017. 62 funds tracked by Wall St. Rank hold FOMX as of Q1 2019.

  • Marshall Wace North America reported no remaining Foamix Pharmaceuticals Ltd. Ordinary Shares position as of Q1 2019 after selling out during the quarter.
  • Marshall Wace North America sold 23,230 Foamix Pharmaceuticals Ltd. Ordinary Shares shares in Q1 2019, an estimated $83K.
  • Marshall Wace North America first reported a position in Foamix Pharmaceuticals Ltd. Ordinary Shares in Q1 2017 and held it in 8 quarters.
  • Marshall Wace North America's Foamix Pharmaceuticals Ltd. Ordinary Shares position peaked at $3.78M in Q4 2017.
  • 62 funds tracked by Wall St. Rank held Foamix Pharmaceuticals Ltd. Ordinary Shares as of Q1 2019.

Based on Marshall Wace North America's 13F filing for Q1 2019, filed 14 May 2019.